An antitumor penicillin derivative inhibits β-catenin levels and cell migration in melanoma cells sensitive and resistant to the BRAF inhibitor dabrafenib

SOFIA BAJICOFF; FLORENCIA CAYROL; MERCEDES DEBERNARDI; CAMILA CHOCAN; MARIA FLORENCIA ARBE; MARCELA VILLAVERDE; CARINA M. DELPICCOLO; NADIA L MARTIREN; ERNESTO G. MATA; VIVIANA C BLANK; LEONOR P. ROGUIN

Congreso; Reunión Anual de Sociedades de Biociencias; 2023

Melanoma is a very aggressive form of skin cancer, with increased metastatic potential and high resistance to cytotoxic agents. In the search for effective treatments for resistant cells, we decided to study the mechanism of action of a previously characterized antitumor penicillin derivative (TAP7f) in different melanoma cells. After evaluating TAP7f cytotoxic potency (IC50 values) and the sensitivity to BRAF and MEK inhibitors, we selected two melanoma cell lines for further studies: A375S and A375R, sensitive and resistant to the BRAF inhibitor dabrafenib. By Western blot assays (WB), higher expression levels of β-catenin and p-ERK were found in A375R cells with respect to A375S cells (p